<DOC>
	<DOCNO>NCT02240212</DOCNO>
	<brief_summary>This Phase Ib , open-label , dose-escalation study determine Maximal tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) combination afuresertib paclitaxel subject recurrent HER2-negative gastric cancer , assess safety preliminary efficacy combination RP2D . Afuresertib show synergistic activity combine paclitaxel vitro vivo model gastric cancer . Dose escalation continue MTD establish . The dose schedule daily ( QD ) dose afuresertib intravenous ( IV ) infusion paclitaxel Dose escalation Part 1 follow 3 + 3 cohort design . A sequential approach conduct explore optimal paclitaxel regimen ( weekly 3weekly schedule ) combine afuresertib . The dose escalation start Cohort A ( afuresertib combine weekly paclitaxel regimen 80 milligram ( mg ) /meter ( ) ^2 day1 , 8,15 , every 4 week ( q4w ) . The start dose Cohort A 125 mg afuresertib QD . Once MTD identify , study move dose Cohort B ( afuresertib combine 3 weekly paclitaxel regimen 175 mg/m^2 day1 , every 3 week ( q3w ) . The start daily dose Cohort B 25 mg less MTD dose Cohort A afuresertib . If tolerate , dose escalation schedule follow Cohort B MTD Cohort reach . If start dose tolerate , dose de-escalation explored MTD Cohort reach . Once two dimension MTD achieve , optimal regimen paclitaxel MTD afuresertib combine paclitaxel base toxicity profile identify . The combination regimen RP2D select follow Part I investigate efficacy safety Part II Expansion Cohort . Once combination dose regimen Part 2 determine , least 20 40 subject enrol dose regimen select follow Part I . Overall response rate ( ORR ) evaluate use Green-Dahlberg design . The design consist one interim analysis . If less 3 response observe initial 20 subject , enrollment terminate due futility ; otherwise , study continue meet planned sample size 40 subject .</brief_summary>
	<brief_title>Study Afuresertib Combined With Paclitaxel Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Provided sign write informed consent Male female &gt; =18 year age diagnosis Performance Status score 0 1 accord Eastern Cooperative Oncology time sign informed consent Able swallow retain orally administer study treatment Women childbearing potential must negative serum pregnancy test within 7 day prior first dose study treatment agree use effective contraception study . Men female partner childbearing potential must either prior vasectomy agree use effective contraception ( Condom [ nonvaginal intercourse partner male female ] OR Doublebarrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) [ sexual intercourse female ] . Abstinence , define sexual inactivity consistent preferred usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Adequate organ system function screen Hematologic system ( Absolute neutrophil count &gt; =1.5 x 10^9/Litre ( L ) , Hemoglobin &gt; =9.0 gram ( g ) /deci ( ) L , Platelets &gt; =100 x 10^9/microL without transfusion past 7 day , prothrombin time/ international normalized ratio ( PT/INR ) partial thromboplastin time ( PTT ) &lt; =1.5 x Upper limit normal [ ULN ] ) , Hepatic system ( Total bilirubin &lt; =1.0x ULN , Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; =2.5x ULN ) , Metabolic system ( Fasting Serum Glucose &lt; 126 milli ( ) g/dL [ 7 millimol/L ] , Hemoglobin A1C &lt; =8 % ) Renal system ( Serum creatinine &lt; = ULN , 24hour urine creatinine clearance &gt; =60 mL/minute [ min ] ) Histologically confirm stomach gastroeosophageal ( GE ) junction cancer document HER2negative ( define immunohistochemistry ( IHC ) 01+ IHC2+ negative fluorescent situ hybridization ( FISH ) test assess local designated central lab ) primary metastatic tumor tissue . Metastatic locally advance , unresectable disease . Subjects must receive firstline platinum/fluoropyrimidine doublet regimen advance gastric cancer exhibit progressive disease ( PD ) , must recover treatmentrelated toxicity . Note : prior XELOX , XP , FOLFOX , SP ( S1+cisplatin ) ) treatment could eligible , priortaxane ineligible . Note : patient refractory disease progression within 6 month adjuvant treatment , previous treatment would consider first line treatment rather adjuvant treatment , patient could enrol study inclusion/exclusion criterion meet . Subjects shall least one measurable disease ( i.e. , present least one measurable lesion ) RECIST version1.1 History another malignancy . Exception : Subjects diseasefree 3 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Prior PI3KAKT mammalian target rapamycin ( mTOR ) pathway target therapy eligible . ( Note : prior vaccine immunotherapy allow must end least 8 week prior study treatment ) . Unresolved toxicity ( Grade &lt; =1 ) prior chemotherapy exception alopecia anemia ( Hemoglobin &gt; 9 g/dL ) . Subjects uncontrolled brain metastasis spinal cord compression . Current use warfarin therapeutic anticoagulation ( Note : low molecular weight heparin permit ) . Presence active gastrointestinal disease ( include gastric cancer ) , condition know interfere significantly absorption , distribution , metabolism , excretion drug . Prior gastrectomy allow . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within six month Screening . Pregnant lactate female . Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Any prohibited medication ( ) Coadministration afuresertib medication sensitive substrate CYP3A4 , OATP1B1 BCRP low therapeutic index prohibit . Coadministration afuresertib medication sensitive substrate CYP2C8 low therapeutic index use caution . History Type 1 diabetes Any major surgery within last four week . QTcF interval &gt; =470 millisecond ( msec ) s. know immediate delay hypersensitivity reaction idiosyncratic reaction drug similar relate afuresertib taxanes . Any contraindication ( identify investigator ) dose paclitaxel define protocol . Any history reduction standard care paclitaxel dose peripheral neuropathy . Known Human Immunodeficiency Virus ( HIV ) infection active hepatitis B C. ( Note : active Hepatitis B virus ( HBV ) infection define ALT/AST equal normal range HBV deoxyribonucleic acid ( DNA ) &gt; =2Ã—10^34 international unit ( IU ) /mL ; active Hepatitis C virus ( HCV ) infection define HCV ribonucleic acid ( RNA ) + ALT/AST normal range ) . Antiviral therapy initiate study treatment , maintain study treatment patient inactive HBV infection . Prophylaxis HBV reactivation recommend accordance establish guideline : AsianPacific census statement HBV 2012 Taiwan health insurance guidance 2013 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>second line treatment</keyword>
	<keyword>oncology</keyword>
	<keyword>AKT inhibitor</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>HER2 ( ErbB2 ) negative advanced gastric cancer</keyword>
	<keyword>Afuresertib</keyword>
</DOC>